1900.6000 10.40 (0.55%)
NSE Jul 17, 2026 15:31 PM
Volume: 157.3K
 

1900.60
0.55%
Emkay
Ipca’s 4QFY26 EBITDA was ahead of our expectations (broadly in line with the consensus’). The beat was driven by higher overall sales, a marginally higher gross margin, as well as lower staff costs.
Ipca Laboratories has gained 29.20% in the last 1 Year
More from Ipca Laboratories Ltd.
Recommended